Leerink Partnrs Issues Positive Forecast for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for shares of BridgeBio Pharma in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.72) per share for the quarter, up from their previous forecast of ($0.73). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $3.28 EPS and FY2029 earnings at $4.88 EPS.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research note on Friday, February 21st. Evercore ISI upped their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Citigroup increased their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. Bank of America increased their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and an average target price of $51.67.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $34.90 on Friday. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $39.47. The firm has a market capitalization of $6.64 billion, a P/E ratio of -12.25 and a beta of 1.07. The company’s fifty day moving average price is $32.68 and its two-hundred day moving average price is $28.29.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 8,500 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $33.19, for a total transaction of $282,115.00. Following the transaction, the chief financial officer now owns 102,464 shares in the company, valued at $3,400,780.16. This represents a 7.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Neil Kumar sold 75,000 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the transaction, the chief executive officer now owns 5,023,447 shares in the company, valued at approximately $168,637,115.79. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,579,739 shares of company stock worth $125,411,901 in the last quarter. 24.66% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BBIO. Creative Planning acquired a new position in BridgeBio Pharma in the 3rd quarter valued at $772,000. Allspring Global Investments Holdings LLC lifted its holdings in BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock valued at $135,000 after purchasing an additional 801 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BridgeBio Pharma by 21.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock valued at $170,000 after purchasing an additional 1,214 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in BridgeBio Pharma by 50.8% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 751,355 shares of the company’s stock valued at $19,129,000 after purchasing an additional 253,101 shares during the last quarter. Finally, Emerald Advisers LLC increased its position in BridgeBio Pharma by 65.6% in the 3rd quarter. Emerald Advisers LLC now owns 1,103,508 shares of the company’s stock valued at $28,095,000 after acquiring an additional 437,164 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.